Qantas Shares Climb as Long-Haul Pilot Deal Eases Strike Concerns 
Western Digital Q4 Earnings Beat Estimates as FY2027 Outlook Tops Expectations 
SanDisk Q4 Earnings Beat Estimates as Q1 Revenue Outlook Meets Expectations 
Cloudflare Stock Jumps 15% as Earnings Beat Estimates, 2026 Outlook Raised 
Delta Flight Makes Emergency Landing in Atlanta After Cockpit Fumes Reported 
UOB Q2 Net Profit Rises 10% as Wealth Management Growth Boosts Earnings 
Alibaba Plans Revenue-Sharing Model for Qwen3.8-Max AI Commercial Users 
Meta Ordered to Pay $567M Over Child Safety Violations in New Mexico 
AMP Shares Surge 13% After Strong Profit and A$150 Million Buyback 
Daimler Truck Q2 Profit Falls 18%, 2026 Outlook Raised 
OpenAI Restricts Astra AI Over Cyberattack Risks 
SoftBank Q1 Profit Beats Forecast as Intel Rally and OpenAI Investments Boost Returns 
DeepSeek to Raise AI API Prices as Demand for New Models Surges 
SK Hynix, Samsung Lead Asian Chip Stock Selloff After Sandisk, Western Digital Outlook 
Siemens Energy Q3 Profit Beats Forecast as AI-Driven Power Demand Fuels Growth 
Airbnb Stock Jumps After Q2 Earnings Beat, Strong 2026 Outlook 
DoorDash Q2 Revenue Jumps 36% as Orders and DashPass Growth Drive Results 
SOUTH SAN FRANCISCO, Calif., March 01, 2018 -- Sunesis Pharmaceuticals, Inc. (Nasdaq:SNSS) today announced that it will host a conference call on Thursday, March 8th, 2018 at 1:30 p.m. Pacific Time to discuss corporate updates and financial results for the fourth quarter and year ended December 31, 2017.
The call can be accessed by dialing (844) 269-7720 (U.S. and Canada) or (574) 990-1148 (international), and entering passcode 8182338.
To access the live audio webcast, or the subsequent archived recording, visit the "Investors and Media - Calendar of Events" section of the Sunesis website at http://ir.sunesis.com. The webcast will be recorded and available for replay on the company's website for two weeks.
About Sunesis Pharmaceuticals
Sunesis is a biopharmaceutical company developing new oncology therapeutics for the treatment of solid and hematologic cancers. Sunesis has built an experienced cancer drug development organization committed to improving the lives of people with cancer. The Company is focused on advancing its novel kinase-inhibitor pipeline, with an emphasis on establishing proof of concept that its oral non-covalent BTK-inhibitor vecabrutinib is effective in ibrutinib-resistant chronic lymphocytic leukemia. Vecabrutinib is currently being evaluated in a Phase 1b/2, open-label, sequential-group, dose-escalation and cohort-expansion study in adults with chronic lymphocytic leukemia and other B-cell malignancies who have progressed after prior therapies. Beyond the development of vecabrutinib, the Company has two other kinase inhibitor programs, including the Takeda-partnered pan-RAF inhibitor TAK-580, which is in solid tumor trials, and Sunesis’ proprietary preclinical PDK1 inhibitor SNS-510, which is in preclinical development with an IND submission planned in 2019. PDK1 is a master kinase that activates other kinases important to cell growth and survival including members of the AKT, PKC, RSK and SGK families.
For additional information on Sunesis, please visit www.sunesis.com.
SUNESIS and the logos are trademarks of Sunesis Pharmaceuticals, Inc.
| Investor and Media Inquiries: Maeve Conneighton Argot Partners 212-600-1902 | Willie Quinn Sunesis Pharmaceuticals Inc. 650-266-3716 | ||
